SCYNEXIS, Inc. (SCYX)
Market Cap | 53.61M |
Revenue (ttm) | 140.14M |
Net Income (ttm) | 67.04M |
Shares Out | 37.75M |
EPS (ttm) | 1.39 |
PE Ratio | 1.02 |
Forward PE | 2.25 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 127,368 |
Open | 1.400 |
Previous Close | 1.410 |
Day's Range | 1.370 - 1.460 |
52-Week Range | 1.350 - 3.870 |
Beta | 1.57 |
Analysts | Buy |
Price Target | n/a |
Earnings Date | May 9, 2024 |
About SCYX
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The co... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resista...
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
JERSEY CITY, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resista...
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
JERSEY CITY, N.J., Jan. 29, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan...
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SCYNEXIS, Inc. ("SCYNEXIS" or "...
Final SCYX Investor Deadline: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK , Jan. 8, 2024 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against SCYNEXIS, Inc. ("Scyn...
SCYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, Jan. 7, 2024 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX
NEW YORK , Jan. 6, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SCYNEXIS, Inc. ("SCYNEXIS" or the "Company") (NASDAQ: SCYX). Such investors are advised to conta...
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy
JERSEY CITY, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SCYNEXIS, Inc. ("SCYNEXIS" or "...
SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit
LOS ANGELES , Jan. 4, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit agai...
SCYNEXIS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $25,000 investing in Scynexis securities between March 31, 2023 and September 22, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh W...
JANUARY 8 FINAL DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SCYNEXIS, Inc. ("SCYNEXIS" or "...
SHAREHOLDER ACTION DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SCYNEXIS, Inc. ("SCYNEXIS" or "...
FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SCYNEXIS, Inc. ("SCYNEXIS" or...
SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $25,000 investing in Scynexis securities between March 31, 2023 and September 22, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh W...
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SCYNEXIS, Inc. ("SCYNEXIS" or...
TOP RANKED ROSEN LAW FIRM Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYX
NEW YORK , Dec. 25, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SCYNEXIS, Inc. (NASDAQ: SCYX) between March 31, 2023 and September ...
IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 22, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SCYNEXIS, Inc. ("SCYNEXIS" or...
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 21, 2023 / Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SCYNEXIS, Inc. ("SCYNEXIS" or "th...
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SCYNEXIS, Inc. ("SCYNEXIS" or...
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SCYNEXIS, Inc. ("SCYNEXIS" or...
FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 13, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SCYNEXIS, Inc. ("SCYNEXIS" or...
ROSEN, A TOP RANKED LAW FIRM, Encourages SCYNEXIS, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SCYX
NEW YORK , Dec. 12, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SCYNEXIS, Inc. (NASDAQ: SCYX) between March 31, 2023 and September ...
IMPORTANT DEADLINE REMIDNER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SCYNEXIS, Inc. ("SCYNEXIS" or ...
FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SCYNEXIS, Inc. ("SCYNEXIS" or ...